Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?
Mené sur 409 patients atteints d'un cancer du pancréas, sur 25 patients présentant une pancréatite chronique et sur 312 témoins sains, cet essai identifie deux signatures basées respectivement sur l'expression dans le sang total de 4 et 10 micro-ARNs, puis évalue, du point de vue de la sensibilité et de la spécificité, leur performance pour détecter un cancer du pancréas
Pancreatic cancer represents the 10th most commonly diagnosed cancer, but is the 4th leading cause of cancer-related death in the United States.1 It is estimated that approximately 45 220 new cases of pancreatic cancer will be diagnosed and that 38 460 people will die of pancreatic cancer in the United States in 2013,1 with an estimated 227 000 deaths from pancreatic cancer occurring worldwide each year.2 The incidence of pancreatic cancer has been slowly increasing over the last decade.2,3 The 1- and 5-year survival rates for pancreatic cancer are about 25% and 5%, respectively, which are the lowest survival rates of all major cancers.1,3
JAMA , éditorial, 2013